Alvotech and Advanz Pharma Strengthen Partnership to Include Three New Biosimilars in Europe
Thursday, May 29, 2025
Alvotech, a global biotechnology firm focused on developing and producing biosimilar medicines, and Advanz Pharma, a UK-based pharmaceutical company specialising in hospital, specialty, and rare disease treatments, have expanded their strategic partnership to include three additional biosimilar candidates for the European market.
The extended agreement covers the supply and commercialisation of biosimilar versions of Ilaris® (canakinumab), used to treat several inflammatory conditions, and Kesimpta® (ofatumumab), a treatment for relapsing forms of multiple sclerosis. A third biosimilar, not yet disclosed, is also included. Under the arrangement, Alvotech will manage product development and supply, while Advanz Pharma will oversee regulatory approvals and marketing across Europe.
The deal includes development and commercial milestone payments that may reach up to US$180 million (approximately EUR 160 million) based on current exchange rates. Both companies will also share future revenues from these products.
This expansion builds on a collaboration first established in 2023, which already includes biosimilars to reference medicines such as Xolair® (omalizumab), Simponi® (golimumab), Entyvio® (vedolizumab), Eylea® (aflibercept), Eylea® HD, Dupixent® (dupilumab), Taltz® (ixekizumab), and Tremfya® (guselkumab).
The existing and new agreements cover all 30 countries within the European Economic Area, as well as the United Kingdom and Switzerland. The collaboration for Xolair® additionally extends to Canada, Australia, and New Zealand.
According to data from IQVIA, the combined addressable market for the biosimilars under the Alvotech–Advanz Pharma agreements is currently valued at over US$13.8 billion in the regions covered.
The partnership continues to support broader access to high-cost biologic treatments, particularly in areas such as rare diseases and specialty medicine, while contributing to the long-term sustainability of healthcare systems in Europe.
Source: globenewswire.com
